CITED2 and prostate cancer: Amongst genes uniquely down-regulated by CBPD-409 versus reader bromodomain inhibitors, we identified NKX3–1, CITED2, and CCND1 that are known for their driver roles in prostate cancer progression42–44 (Figures 5A and S6D).